Unibio USA ApS: Financial statements 2023
CVR: 38179845
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
Unibio USA ApS (CVR 38179845) has filed annual accounts for 2023. In 2023, the company reported a net result of DKK -17,000 compared with DKK -34,000 the year before. Equity in the 2023 report amounted to DKK 71,000. The solvency ratio was 82.6%.
- Profit/Loss
- DKK -17,000
- Equity
- DKK 71,000
- Total Assets
- DKK 86,000
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | - | -17K | 71K | - |
| 2022 | - | -18K | -34K | 88K | 0 |
| 2021 | - | -15K | -12K | 72K | 0 |
| 2020 | - | -14K | -11K | 8K | 0 |
| 2019 | - | -15K | -12K | 19K | 0 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
Unibio USA ApS has published its annual report for 2022. Gross profit came to DKK -18,000, and the net result was DKK -34,000.
About Unibio USA ApS
Unibio USA ApS is a Danish company of the type Anpartsselskab based in Roskilde, founded in 2016. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of David Richard Henstrom and Søren Olrik Eklund. The company is owned by UNIBIO A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a net result of DKK -20,000 compared with DKK -26,000 the year before. Equity in the 2025 report amounted to DKK 25,000.